Targeted Oncology· @TargetedOnc · X·· 22 hours agoScore70
Body
One question I would ask the KEYNOTE-B49 investigators:
Did the PFS improvement translate into better symptom control, longer time to deterioration or improved quality of life?
When OS is neutral, patient-reported outcomes become especially important.
#ESMO26 #BreastCancer
54 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com